An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings.

PubWeight™: 0.90‹?›

🔗 View Article (PMC 4164000)

Published in J Int AIDS Soc on September 08, 2014

Authors

Kathleen M MacQueen1, Elizabeth E Tolley2, Derek H Owen3, K Rivet Amico4, Kathleen M Morrow5, Thomas Moench6, David R Friend7, Barbara Friedland8

Author Affiliations

1: Social and Behavioral Health Sciences, FHI 360, Durham, NC, USA; kmacqueen@fhi360.org.
2: Social and Behavioral Health Sciences, FHI 360, Durham, NC, USA.
3: Contraceptive Technology Institute, FHI 360, Durham, NC, USA.
4: Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
5: Centers for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, RI, USA; Department of Psychiatry & Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA.
6: Reprotect Inc, Baltimore, MD, USA; The Johns Hopkins University, Baltimore, MD, USA.
7: Product Development, CONRAD, Arlington, VA, USA.
8: Population Council, New York, NY, USA.

Articles cited by this

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84

Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care (1986) 22.65

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03

Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2013) 13.72

A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med (2001) 9.98

Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract (2005) 8.07

Measuring sexual behaviour: methodological challenges in survey research. Sex Transm Infect (2001) 6.21

Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (2012) 4.26

What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44

Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther (2001) 2.95

Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One (2014) 2.85

Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44

Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03

Ethics. Fair benefits for research in developing countries. Science (2002) 2.02

The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). J Behav Med (2007) 1.98

A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS One (2010) 1.97

Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60

Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav (2012) 1.44

State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev (2012) 1.37

State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr (2012) 1.37

Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav (2012) 1.35

Women's Autonomy and Informed Consent in Microbicides Clinical Trials. J Empir Res Hum Res Ethics (2006) 1.24

Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep (2013) 1.22

Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach. J Med Ethics (2010) 1.15

The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav (2011) 1.10

Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav (2014) 1.09

Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav (2014) 1.00

An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda. J Acquir Immune Defic Syndr (2014) 0.98

The art and science of scale development in health education research. Health Educ Res (1995) 0.95

Malicious whites, greedy women, and virtuous volunteers: negotiating social relations through clinical trial narratives in South Africa. Med Anthropol Q (2013) 0.95

Behaviour change counselling for ARV adherence support within primary health care facilities in the Western Cape, South Africa. AIDS Behav (2012) 0.94

Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels. J Clin Pharmacol (2013) 0.93

International perspectives on the collection, storage, and testing of human biospecimens in HIV research. IRB (2008) 0.92

The exploitation of "Exploitation" in the tenofovir prep trial in Cameroon: Lessons learned from media coverage of an HIV prevention trial. J Empir Res Hum Res Ethics (2010) 0.90

An examination of the psychometric properties of the Antiretroviral General Adherence Scale (AGAS) in two samples of HIV-infected individuals. J Assoc Nurses AIDS Care (2009) 0.89

Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. AIDS Care (2014) 0.87

Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study. AIDS Behav (2014) 0.79